Maidment, Ian - Aston University - School of Life & Health Sciences, Pharmacy

个人简介

Postgraduate Certificate in Higher Education (distinction), Aston University, 2015 PhD entitled - Medication-related adverse events in older people with dementia; causes and possible solutions, Aston University, 2013 MA in Health Service Research with Merit, University of Kent, 2010 Diploma Management Studies (distinction), Christchurch University, Canterbury, 2004 Diploma Psychiatric Pharmacy, De Montfort University, Leicester, 1996 BPharm (2:1), University of Bath, 1986 2012 – date: Senior Lecturer in Clinical Pharmacy, Pharmacy, Aston University. 2007 – 2011: Senior Pharmacist / Clinical Lead for R&D, Kent & Medway NHS and Social Care Partnership Trust. 2002 – 2007: Chief Pharmacist for East Kent Partnership NHS Trust. 2000 – 2002: Pharmacy services manager (mental health), Kent & Canterbury Hospital. 1997 – 2000: Mental Health Pharmacist, Norfolk and Waveney Mental Health Trust. 1996 – 1997: Clinical Audit Pharmacist, Royal Berkshire Hospital. 1994 – 1996: Clinical Pharmacist, Thanet Hospital. 1993 – 1994: Locum Pharmacist, St Mary’s Hospital, Isle of Wight. 1988 – 1993: Community Pharmacy Manager. 1987 – 1988: Basic Grade Pharmacist, Lewisham Hospital. 1986 – 1987: Industrial / Hospital Pre-registration Pharmacist.

研究领域

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Medication errors in mental health and dementia – widely published in this field and undertaken qualitative and quantitative research. This includes an analysis of all medication errors reported by Mental Health Trusts to the NPSA in a single year, which was part of Themed Review of Medication Safety Incidents (Safety in Doses; NPSA, 2009 – available on www.nrls.npsa.nhs.uk/resources/?EntryId45=61625). Medication management in dementia – linked with international leaders in this field. Chair of grant-writing group, which is supported by Dementia and Neurogenerative Diseases (DeNDRoN). Pharmacological interventions for agitation in dementia – co-principal investigator for 1st in world CTIMP (clinical trial of an investigation medicinal product) studying a pharmaceutical agent in dementia. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035185 Anti-cholinergic burden (ACB) – investigator on two recently published trials, which studied the link between ACB, and cognition and mortality (one study, which identified an association between mortality and ACB, received widespread international publicity). http://www.ncbi.nlm.nih.gov/pubmed/21926432 http://www.ncbi.nlm.nih.gov/pubmed/21707557 Member of the Dementia and Neurogenerative Diseases (DeNDRoN) Dementia Research Network Clinical Studies Group. Member of trial monitoring committee for Drug Safety Research Unit (DSRU) observational trial